Tags

Type your tag names separated by a space and hit enter

Cytokine storm intervention in the early stages of COVID-19 pneumonia.
Cytokine Growth Factor Rev. 2020 06; 53:38-42.CG

Abstract

Clinical intervention in patients with corona virus disease 2019 (COVID-19) has demonstrated a strong upregulation of cytokine production in patients who are critically ill with SARS-CoV2-induced pneumonia. In a retrospective study of 41 patients with COVID-19, most patients with SARS-CoV-2 infection developed mild symptoms, whereas some patients later developed aggravated disease symptoms, and eventually passed away because of multiple organ dysfunction syndrome (MODS), as a consequence of a severe cytokine storm. Guidelines for the diagnosis and treatment of SARS-CoV-2 infected pneumonia were first published January 30th, 2020; these guidelines recommended for the first time that cytokine monitoring should be applied in severely ill patients to reduce pneumonia related mortality. The cytokine storm observed in COVID-19 illness is also an important component of mortality in other viral diseases, including SARS, MERS and influenza. In view of the severe morbidity and mortality of COVID-19 pneumonia, we review the current understanding of treatment of human coronavirus infections from the perspective of a dysregulated cytokine and immune response.

Authors+Show Affiliations

Department of Endocrinology, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China.Department of Endocrinology, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China.Department of Nephrology, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China.Department of Endocrinology, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China.Department of Endocrinology, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China.Department of Hematology, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China.Translational Medicine Center, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China.Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine. Nanjing, Jiangsu, China.Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.Department of Respiratory Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.Translational Medicine Center, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China. Electronic address: wj6373@hotmail.com.Department of Endocrinology, Air Force Hospital of Eastern Theater Command, Nanjing, Jiangsu, China. Electronic address: wap454hospital@163.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32360420

Citation

Sun, Xinjuan, et al. "Cytokine Storm Intervention in the Early Stages of COVID-19 Pneumonia." Cytokine & Growth Factor Reviews, vol. 53, 2020, pp. 38-42.
Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38-42.
Sun, X., Wang, T., Cai, D., Hu, Z., Chen, J., Liao, H., Zhi, L., Wei, H., Zhang, Z., Qiu, Y., Wang, J., & Wang, A. (2020). Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine & Growth Factor Reviews, 53, 38-42. https://doi.org/10.1016/j.cytogfr.2020.04.002
Sun X, et al. Cytokine Storm Intervention in the Early Stages of COVID-19 Pneumonia. Cytokine Growth Factor Rev. 2020;53:38-42. PubMed PMID: 32360420.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cytokine storm intervention in the early stages of COVID-19 pneumonia. AU - Sun,Xinjuan, AU - Wang,Tianyuan, AU - Cai,Dayong, AU - Hu,Zhiwei, AU - Chen,Jin'an, AU - Liao,Hui, AU - Zhi,Liming, AU - Wei,Hongxia, AU - Zhang,Zhihong, AU - Qiu,Yuying, AU - Wang,Jing, AU - Wang,Aiping, Y1 - 2020/04/25/ PY - 2020/03/12/received PY - 2020/03/22/revised PY - 2020/04/09/accepted PY - 2020/5/4/pubmed PY - 2020/7/1/medline PY - 2020/5/4/entrez KW - COVID-19 KW - Cytokine storm KW - Inflammation KW - Lung damage KW - SARS-CoV2 SP - 38 EP - 42 JF - Cytokine & growth factor reviews JO - Cytokine Growth Factor Rev VL - 53 N2 - Clinical intervention in patients with corona virus disease 2019 (COVID-19) has demonstrated a strong upregulation of cytokine production in patients who are critically ill with SARS-CoV2-induced pneumonia. In a retrospective study of 41 patients with COVID-19, most patients with SARS-CoV-2 infection developed mild symptoms, whereas some patients later developed aggravated disease symptoms, and eventually passed away because of multiple organ dysfunction syndrome (MODS), as a consequence of a severe cytokine storm. Guidelines for the diagnosis and treatment of SARS-CoV-2 infected pneumonia were first published January 30th, 2020; these guidelines recommended for the first time that cytokine monitoring should be applied in severely ill patients to reduce pneumonia related mortality. The cytokine storm observed in COVID-19 illness is also an important component of mortality in other viral diseases, including SARS, MERS and influenza. In view of the severe morbidity and mortality of COVID-19 pneumonia, we review the current understanding of treatment of human coronavirus infections from the perspective of a dysregulated cytokine and immune response. SN - 1879-0305 UR - https://www.unboundmedicine.com/medline/citation/32360420/Cytokine_storm_intervention_in_the_early_stages_of_COVID_19_pneumonia_ DB - PRIME DP - Unbound Medicine ER -